Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Patients With Peritoneal Mesothelioma Lack Epidermal Growth Factor Receptor Tyrosine Kinase Mutations That Would Make Them Sensitive To Tyrosine Kinase Inhibitors.

Neetu Kalra, Ali Ashai, L. Xi, J. Zhang, Itzhak Avital, M. Raffeld, Raffit Hassan
Published 2012 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The epidermal growth factor receptor (EGFR) is a promising target for cancer therapy. The presence of certain somatic mutations in the tyrosine kinase (TK) domain of the EGFR gene is associated with clinical response to TK inhibitors (TKI) in patients with lung adenocarcinoma. In this study we evaluated the status of somatic mutations in the entire TK domain of the EGFR gene by direct sequencing using early passage peritoneal mesothelioma cells, established cell lines as well as 33 peritoneal mesothelioma tumor samples. No novel mutations were found in the cell lines. Sequence analysis of the EGFR TK domain revealed the presence of a silent polymorphism (c.2607G → A, Q787Q) at exon 20 of both peritoneal mesothelioma cell lines as well as tumor specimens. The frequency of genotypes AA and GA was 42.8 and 57.2% in the cell lines and 33.3 and 57.6% in tumor specimens, respectively. The TKI erlotinib showed an IC50 in the range of 10-50 µM in five out of the seven cell lines with a GA genotype while all five cell lines with the AA genotype had an IC50 >50 µM. Of the 33 peritoneal mesothelioma tumor samples analyzed none had an EGFR TKI sensitizing mutation and only one specimen showed an earlier reported somatic mutation at codon 850 in exon 21 of the EGFR gene. Our data show that patients with peritoneal mesothelioma do not harbor somatic mutations in the EGFR TK domain that would make them sensitive to EGFR TKI.
This paper references
10.1093/oxfordjournals.annonc.a058685
National Cancer Institute of Canada Clinical Trials Group.
(1994)
10.1002/jso.21787
Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research
D. Baratti (2011)
10.1016/j.lungcan.2011.04.005
EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.
Xiao-li Jia (2011)
10.1186/1471-2407-9-212
Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma
A. Longatto-Filho (2008)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.3892/OR.19.1.65
Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.
T. Taguchi (2008)
10.1016/J.SURG.2006.09.009
Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer.
C. Tzeng (2007)
10.1016/j.ejso.2008.09.010
Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.
H. Yano (2009)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1111/j.1742-4658.2009.07448.x
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
T. Mitsudomi (2010)
10.1007/s00432-008-0384-4
Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma
K. Okuda (2008)
10.1634/THEONCOLOGIST.7-SUPPL_4-31
Epidermal growth factor receptor dependence in human tumors: more than just expression?
C. Arteaga (2002)
10.1056/NEJMOA040938
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
T. Lynch (2004)
10.1200/JCO.2007.15.6695
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
Chung-Yi Yang (2008)
10.1245/s10434-008-0206-6
Novel and Existing Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor are Predictors of Optimal Resectability in Malignant Peritoneal Mesothelioma
J. Foster (2008)
10.1016/S1556-0864(15)30375-0
Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer
W. Zhang (2006)
10.1016/J.MOLMED.2004.08.008
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
A. Gazdar (2004)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/j.ejca.2010.06.130
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
F. Perrone (2010)
10.1080/10408440903044928
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
10.1097/PAT.0b013e328344e61b
Epidermal growth factor receptor mutation in gastric cancer
Zhimin Liu (2011)
10.1016/j.jss.2007.09.001
EGFR polymorphism of the kinase domain in Japanese lung cancer.
H. Sasaki (2008)
10.1016/J.LUNGCAN.2005.10.016
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
A. Destro (2006)
IDENTIFICATION OF G 2607 A MUTATION IN EGFR GENE WITH A SIGNIFICATIVE RATE IN MOROCCAN PATIENTS WITH NASOPHARYNGEAL CARCINOMA
F. Naji (2010)
10.1002/ijc.21271
Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma
J. Cortese (2006)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
10.1038/modpathol.3800067
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
10.1186/1477-7819-8-88
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma
J. Foster (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar